Loading...
•
Jun 30, 2025
ImmunityBio Q2 2025 Earnings Report
ImmunityBio reported strong commercial traction with 60% revenue growth in Q2 2025 as net loss narrowed year-over-year.
Key Takeaways
ImmunityBio generated $26425000 in total revenue in Q2 2025 driven primarily by ANKTIVA product sales, while net loss attributable to common stockholders was $92555000 as operating costs remained elevated.
Total revenue increased to $26425000, up 60% sequentially in Q2 2025. :contentReference[oaicite:0]{index=0}
Net loss narrowed to $92555000 from prior year period. :contentReference[oaicite:1]{index=1}
Product revenue, net climbed to $26421000 reflecting ANKTIVA adoption. :contentReference[oaicite:2]{index=2}
Cash and equivalents ended at $153658000 improving liquidity. :contentReference[oaicite:3]{index=3}
Revenue by Segment
Forward Guidance
The company continues to pursue regulatory milestones and expand commercialization while managing operating expenses and investing in pipeline development.
Positive Outlook
- Strong sequential revenue growth and expanding commercialization of ANKTIVA. :contentReference[oaicite:4]{index=4}
- Increased cash position of $153.7M supports ongoing operations. :contentReference[oaicite:5]{index=5}
- Regulatory progress in the UK with marketing authorization for ANKTIVA. :contentReference[oaicite:6]{index=6}
- Pipeline advancement with NSCLC randomized trial initiation. :contentReference[oaicite:7]{index=7}
- Lymphopenia program progression with supportive FDA feedback. :contentReference[oaicite:8]{index=8}
Challenges Ahead
- Net losses remain significant in Q2 2025. :contentReference[oaicite:9]{index=9}
- Operating costs and expenses elevated at $97.7M. :contentReference[oaicite:10]{index=10}
- Regulatory challenges persist with papillary-only sBLA. :contentReference[oaicite:11]{index=11}
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...